PMID: 7518340Jul 15, 1994Paper

Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen

Cancer
E I LahtiT J Laatikainen

Abstract

Insulin-like growth factor I (IGF-I) is a potent mitogen for breast cancer cells. The majority of IGF-I in plasma is bound to IGF binding proteins (IGFBPs), which modulate the biologic effects of IGF-I. Plasma concentrations of IGF-I, IGFBP-I, and IGFBP-3 were compared between 40 postmenopausal breast cancer patients receiving long term tamoxifen therapy and 39 breast cancer patients receiving no hormonal treatment. In an additional group of seven patients, serum levels of IGF-I and IGFBP-1 were determined before and during treatment at 6 and 12 months. The tamoxifen and the control groups did not differ with respect to age, parity, age at menopause, or body mass index. There were no significant differences in the mean concentrations (+/- standard error of the mean) of IGF-I (10.0 +/- 0.4 nmol/l and 11.2 +/- 0.5 nmol/l, respectively) and IGFBP-3 (3.2 +/- 0.1 mg/l and 3.1 +/- 0.1 mg/l, respectively), whereas the mean value of IGFBP-1 was significantly higher in the tamoxifen group (6.0 +/- 0.6 micrograms/l versus 2.8 +/- 0.3 micrograms/L, P = 0.0001). No significant differences were found in the insulin levels. During the treatment, concentrations of IGF-I decreased at 6 months and began increasing at 12 months. IGFBP-1 levels i...Continue Reading

References

Mar 1, 1991·Canadian Journal of Physiology and Pharmacology·F W Scott, E B Marliss
Jul 1, 1990·Physiological Reviews·V R Sara, K Hall
May 1, 1990·Clinical Endocrinology·R KoistinenM Seppälä
Oct 11, 1991·The Journal of Clinical Endocrinology and Metabolism·D R ClemmonsW H Busby
Nov 7, 1990·Journal of the National Cancer Institute·M PollakR Margolese
Dec 1, 1986·The Journal of Clinical Investigation·R C Baxter, J L Martin
Sep 1, 1987·The Journal of Clinical Endocrinology and Metabolism·R C Baxter, C T Cowell
Feb 1, 1988·The Journal of Clinical Endocrinology and Metabolism·A M SuikkariM Seppälä
Dec 1, 1988·The Journal of Clinical Endocrinology and Metabolism·W H BusbyD R Clemmons
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R C Baxter, J L Martin
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·R G ElginD R Clemmons
Mar 1, 1986·Endocrinology·E M RutanenM Seppälä
Feb 1, 1985·The American Journal of Medicine·T G UntermanL S Phillips
Oct 1, 1965·The Journal of Clinical Endocrinology and Metabolism·V HerbertS J Bleicher
May 1, 1983·The Journal of Clinical Endocrinology and Metabolism·A C MosesD P Aden
Feb 1, 1989·Lancet·H J Stewart, G M Knight

❮ Previous
Next ❯

Citations

Sep 9, 1999·Journal of Surgical Oncology·A S Heerdt, P I Borgen
Aug 22, 1996·International Journal of Cancer. Journal International Du Cancer·S I HelleP E Lønning
Nov 19, 2013·Pituitary·Irida Balili, Ariel Barkan
Jul 3, 2013·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Kirsten H LimesandAndrew Fribley
Apr 17, 2002·Maturitas·R Druckmann, U D Rohr
Aug 14, 2003·Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society·Anders Juul
Aug 2, 2002·Breast Cancer Research and Treatment·Pamela J GoodwinNicky Hood
Sep 29, 2001·Molecular Pathology : MP·M J CampbellA J Leathem
Jan 1, 1995·Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum·I T Whicher, R E Banks
Dec 23, 2015·Molecular and Cellular Endocrinology·Ali Vaziri-Gohar, Kevin D Houston
Aug 9, 1995·International Journal of Cancer. Journal International Du Cancer·R R Kazer
Mar 15, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S I HelleP E Lønning
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·V C Jordan, M Morrow
Jul 13, 2012·The Cochrane Database of Systematic Reviews·Chen MaoJin Ling Tang
Jun 1, 1995·International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics·V J Assikis, V C Jordan
Jan 1, 1995·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·A V Lee, D Yee

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.